HAIs

Rebecca Leach, RN, BSN, MPH, CIC, speaks to Infection Control Today about dealing with respiratory illnesses during the flu season.

Both C. auris and carbapenem-resistant Acinetobacter are quite hardy in the environment. It takes a lot to control spread.

Infection preventionists keeping an eye on coronavirus.

Investigators wanted to find out how well infection preventionists (IPs) are used in antimicrobial stewardship programs (ASPs). They also sought out to take a look at what other members of ASPs think about IPs. The answer to both questions was “not much.”

Patients A and B were both older than 50, suffered from multiple comorbidities, and were residents of long-term care facilities. Both died.

Doffing protocols for treating patients with infections caused by methicillin-resistant Staphylococcus aureus (MRSA) appear to help ward off other healthcare-associated infections (HAIs), but how potent that effect might be remains uncertain.

Further evidence of the importance of patient hand hygiene in the fight against hospital-acquired infections.

It’s not a cure for Clostridiodies difficile, but it’s certainly a huge step toward finding one for the deadly infection that claims 15,000 lives a year in the United States alone, according to investigators who say they have identified the toxin that the most virulent strains of C. diff releases.

Hybrid simulation models have a lot of potential to unlock the best approaches to combat healthcare-acquired infections.

Sarah Baron, MD, authored a study on asymptomatic C. diff carriers.

An increase in prevalence in healthcare settings across the continuum of care over several decades has resulted in MRSA and other multidrug-resistant organisms (MDROs) being given priority as targets of reduction efforts by several regulatory and advisory bodies. These include the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA) and the Centers for Disease Control and Prevention (CDC).

An increase in prevalence in healthcare settings across the continuum of care over several decades has resulted in MRSA and other multidrug-resistant organisms (MDROs) being given priority as targets of reduction efforts by several regulatory and advisory bodies. These include the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA) and the Centers for Disease Control and Prevention (CDC).